NCT01102452已完成不适用
A Randomized, Two-Regimen, Crossover, Comparative Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in 24 Patients With Diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The daily blood glucose level will be monitored by the CGMS (continuous glucose monitoring system)device
研究概览
简要总结
To evaluate the result of PPB-R-203-02 based noodle and commercially available wet noodle on blood glucose control in 24 patients with diabetes for 2 days.
详细描述
The MiniMed Medtronic CGMS (continuous glucose monitoring system), the first model approved by FDA, was used for subcutaneous glucose monitoring. The CGMS continually measures the glucose concentration of the interstitial fluid every 10 seconds and then stores an average glucose value for each 5 minutes period, for a total of up to 288 measurements each day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes mellitus patient.
- •Aged between 20 to 65 years old.
- •Informed consent form signed.
排除标准
- •A recent history of drug or alcohol abuse.
- •Sensitivity to analogous product.
- •Serious cardiovascular disorders.
- •Participation in another clinical investigation study.
- •Ongoing influenza, autoimmune disease and other metabolic diseases.
- •Pregnant or lactating women.
- •Individuals are judged by the investigators or co-investigator to be undesirable as subjects.
结局指标
主要结局
The daily blood glucose level will be monitored by the CGMS (continuous glucose monitoring system)device
时间窗: 2 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
A Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With DiabetesDiabetes MellitusNCT01065402Pharma Power Biotec Co., Ltd.20
招募中
3 期
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06430866Amgen154
已完成
1 期
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady StateHealthy SubjectsBioavailabilityPharmacokineticsNCT01121926Labopharm Inc.30
已完成
1 期
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)HealthyNCT01121900Labopharm Inc.26
已完成
1 期
A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult VolunteersHealthyNCT01241409Johnson & Johnson Pharmaceutical Research & Development, L.L.C.78